Skip to main content
SpringerLink
Log in

Newer Antipsychotic Drugs

A Review of their Pharmacology and Therapeutic Potential

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Despite the enormous benefits provided by antipsychotic medication in the management of schizophrenia, available compounds have serious limitations. Firstly, they are not always effective. Secondly, positive psychopathological symptoms may benefit more than negative or deficit symptoms. Thirdly, antipsychotics are generally associated with a variety of neurological adverse effects.

Three drugs have recently been or are close to being introduced into widespread clinical use: clozapine, risperidone and remoxipride. Each of these compounds appears to have some advantages over traditional antipsychotic agents, particularly in terms of reduced propensity to induce adverse neurological effects. All three drugs have been shown to be clinically effective in large scale trials. Future clinical trials are required to establish their relative merits in comparison with one another.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bersani G, Bresa GM, Meco G, Marini S, Pozzi F. Combined serotonin-5HT2 and dopamine D-2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone. Human Psychopharmacology 5: 225–231, 1990

    Article  Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, et al. Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R55667), a new selective 5-HT2 receptor blocking agent. Current Therapeutic Research 40: 492–499, 1986

    Google Scholar 

  • Borison R. Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. Presented at First International Risperidone Investigators Meeting. Paris, France, March 9–10, 1992

  • Chouinard G, Jones B, Remington G, Bloom D, Addington D, et al. A Canadian Multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 13: 25–40, 1993

    Article  PubMed  CAS  Google Scholar 

  • Christisen GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 17: 217–246, 1991

    Google Scholar 

  • Coward DM, Imperato A, Urwyler S, White TG. Biochemical and behavioral properties of clozapine. Psychopharmacology 99: S6–S12, 1989

    Article  PubMed  Google Scholar 

  • Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 41: 369–371, 1991

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Wiesel SA, Nordstrom AL, Sedvall G. D-1 and D-2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: 528–531, 1989

    Article  Google Scholar 

  • Gelders YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia. British Journal of Psychiatry 155 (Suppl. 5): 33–36, 1989

    Google Scholar 

  • Heinrich K, Klieser E, Lehmann E, Kinzler E. Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, September 1990

  • Janssen PAJ, Niemegeers EJE, Awouters E, Schellekens KHL, Megens AAHP, et al. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 244: 685–693, 1988

    PubMed  CAS  Google Scholar 

  • Kane JM, Cooper TB, Sachor EJ, Halpern FS, Bailine S. Clozapine plasma levels and prolactin response. Psychopharmacology 73: 184–187, 1981

    Article  PubMed  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789–796, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kane J. The efficacy of clozapine in the treatment of schizophrenia: a long term perspective. Journal of Clinical Psychiatry 8: 9–14, 1990

    Google Scholar 

  • Kay SR, Fiszbin A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13: 261–276, 1987

    PubMed  CAS  Google Scholar 

  • King DJ, Blomqvist M, Cooper SJ, Doherty MM, Mitchell MJ, et al. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia. Psychopharmacology 107: 175–179, 1992

    Article  PubMed  CAS  Google Scholar 

  • Kohler C, Hall H, Magnusson O, Lewander T, Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 27–36, 1990

    Article  Google Scholar 

  • Lapierre YD, Nair NPV, Awad AG, Chouinard G, Saxena B, et al. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia — A Canadian multicentre trial. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 72–77, 1990

    Article  Google Scholar 

  • Lewander T, Westerbergh S-E, Morrison D. Clinical profile of remoxipride. A combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 92–98, 1990

    Article  Google Scholar 

  • Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels PJ, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel anti-psychotics risperidone and ocaperidone. Molecular Pharmacology 41: 494–508, 1992

    PubMed  CAS  Google Scholar 

  • Lindstrom LH. The effect of long-term treatment of clozapine in schizophrenia: a retrospective study of 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica 77: 524–529, 1987

    Article  Google Scholar 

  • Lieberman J, Alvir J. A report of clozapine-induced agranulocytosis in the United States. Drug Safety (Suppl. 7): 1–2, 1992

  • Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, et al. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 158: 503–510, 1991

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Yunis J, Egea E, Conoso RT, Kane JM, et al. HLA B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 47: 945–948, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lopez-Ibor Alino JJ. Risperidone: Safety and side effect profile. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992

  • Marder SR. Risperidone: efficacy on positive and negative symptoms. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992a

  • Marder SR. Risperidone: clinical development: North American results. Clinical Neuropharmacology 15 (Suppl.): 92A–93A, 1992b

    Article  PubMed  Google Scholar 

  • Mattes JA. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to two years. Journal of Clinical Psychiatry 50: 389–391, 1989

    PubMed  CAS  Google Scholar 

  • McElroy SL, Dessain EC, Pope HG, Cole JO, Keck PE, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder and schizophrenia. Journal of Clinical Psychiatry 52: 411–414, 1991

    PubMed  CAS  Google Scholar 

  • Meltzer HY. Dimensions of outcome with clozapine. British Journal of Psychiatry 160 (Suppl.): 46–53, 1992

    Google Scholar 

  • Mertens C. Long-term experience with risperidone. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992

  • Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, et al. Therapeutic effect and safety of increasing doses of risperidone (R 64 766) in psychotic patients. Psychopharmacology 99: 445–449, 1989

    Article  PubMed  CAS  Google Scholar 

  • Moller HJ. Incidence of EPS under risperidone therapy. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992

  • Morrison D, Englund A, Lawrie V, Lewander T, Schlachet A, et al. Safety evaluation in both short and long-term treatment of schizophrenia with remoxipride. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 164–169, 1990

    Article  Google Scholar 

  • Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects in the treatment of schizophrenia and tardive dyskinesia. A retrospective study of 387 patients. Psychopharmacology 99: S73–S76, 1989

    Article  PubMed  Google Scholar 

  • Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 10: 799–812, 1962

    Article  Google Scholar 

  • Owen RR, Beake BJ, Marby D, Dessain EC, Cole JO. Response to clozapine in chronic psychotic patients. Psychopharmacology Bulletin 25: 253–256, 1989

    PubMed  Google Scholar 

  • Patris M, Agussol P, Alby JM, Brion S, Burnat G, et al. A double-blind multicenter comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 78–82, 1990

    Article  Google Scholar 

  • Pfeiffer RF, Kang J, Graber B, Hoffman R, Wilson J. Clozapine for psychosis in parkinson’s disease. Movement Disorders 5: 239–242, 1990

    Article  PubMed  CAS  Google Scholar 

  • Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Archives of General Psychiatry 49: 345–361, 1992

    Article  PubMed  CAS  Google Scholar 

  • Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA. On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Safety 7 (Suppl. 1) 33–44, 1992

    Article  PubMed  Google Scholar 

  • Richelson E. Pharmacology of neuroleptics in use in the United States. Journal of Clinical Psychiatry 46: 8–13, 1985

    PubMed  CAS  Google Scholar 

  • Schotte A, de Bruyckere K, Janssen PFM, Leysen JE. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Research 500: 295–301, 1989

    Article  PubMed  CAS  Google Scholar 

  • Sokoloff P, Giros B, Martres MP, Bouthenet M-L, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sunahara RK, Guan H-C, O’Dowd BF, Seaman P, Lawrier LG, et al. Cloning of the gene for human dopamine D5 receptor with higher affinity for dopamine than Dj. Nature 350: 614–616, 1991

    Article  PubMed  CAS  Google Scholar 

  • Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biological Psychiatry 32: 270–280, 1992

    Article  PubMed  CAS  Google Scholar 

  • Van-Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seaman P, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614, 1991

    Article  PubMed  CAS  Google Scholar 

  • Wadworth AN, Heel RC. Remoxipride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in schizophrenia. Drugs 40: 863–879, 1990

    Article  PubMed  CAS  Google Scholar 

  • Walinder J, Holm A-C. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 158–163, 1990

    Article  Google Scholar 

  • Watling KJ, Beer MS, Newberry NR. Interaction of the atypical neuroleptic clozapine with five HT-3 receptors in the cerebral cortex and superior cervical ganglion of the rat. European Journal of Pharmacology 182: 465–472, 1991

    Article  Google Scholar 

  • Wolk SI, Douglas CJ. Clozapine treatment of psychosis in parkinson’s disease: a report of five consecutive cases. Journal of Clinical Psychiatry 53: 373–376, 1992

    PubMed  CAS  Google Scholar 

  • Wolters EC, Hurvitz TA, Peppard RF, Calne DB. Clozapine: an antipsychotic agent in parkinson’s disease? Clinical Neuropharmacology 12: 83–90, 1989

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Hillside Hospital and Albert Einstein College of Medicine, Glen Oaks, New York, 11004, USA

    John M. Kane

Authors
  1. John M. Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kane, J.M. Newer Antipsychotic Drugs. Drugs 46, 585–593 (1993). https://doi.org/10.2165/00003495-199346040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199346040-00002

Keywords

Search

Navigation